Postoperative Pain Management on Uvulopalatopharyngoplasty Patients
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is a randomized controlled study, aimed to investigate the effects of dinalbuphine
sebacate (DS) on patients having uvulopalatopharyngoplasty (UPPP). DS is a prodrug of
nalbuphine, a mixed agonist-antagonist opioid. The mean absorption time for the complete
release of DS into systemic circulation is approximately 145 h, which could theoretically
provide extended analgesic effects for up to 6 days. Patients diagnosed with obstructive
sleep apnea are generally associated with higher risks towards opioid side effects,
especially respiratory depression. Post-UPPP pain managing should be cautiously arranged and
executed. We hypothesize that the combination of our routine practice and DS will improve the
outcomes after Uppp.